Obesity Healthcare Report
Obesity Healthcare Report
GLP-1 therapies are rapidly dominating the obesity market.
The obesity drug market is experiencing rapid expansion fueled by innovative GLP-1 therapies from leaders like Novo Nordisk and Eli Lilly. Projections indicate substantial growth to a $60 billion market by 2032, driven by new treatments offering efficacy comparable to bariatric surgery with fewer side effects.
In this report, Morningstar researchers examine two competing companies with obesity and their impact on the global obesity drug market.
Download the report to gain comprehensive insights into the booming obesity drug market and the future of obesity treatment.
What's Inside:
What's Inside:
- Insights into the surge in demand for new-generation medications rivaling bariatric surgery.
Analysis of key players Novo Nordisk and Eli Lilly, leaders in GLP-1 therapy innovation.
Projections for a $60 billion market by 2032, driven by advancements and competition in obesity treatment.